microcephaly-brachydactyly-kyphoscoliosis syndrome
MONDO:0018091
Microcephaly-brachydactyly-kyphoscoliosis syndrome is characterized by profound intellectual deficit in association with microcephaly, short stature, brachydactyly type D, a flattened occiput, downslanting palpebral fissures, low-set large ears, a broad prominent nose and kyphoscoliosis. It has been described in three sisters. The disorder is likely to be transmitted as an autosomal recessive trait.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Viljoen–Kallis–Voges syndrome
Viljoen–Kallis–Voges syndrome, also known as microcephaly-brachydactyly-kyphoscoliosis syndrome, is a very rare genetic disorder which is characterized by severe intellectual disabilities, microcephaly, low height/short stature, brachydactyly type D, flat occiput, down-slanting palpebral fissures, low-set prominent ears, a broad nose, and kyphoscoliosis. Additional symptoms that appear in at least 80% of affected individuals include decreased muscle mass, dolichocephaly, a high and narrow palate, malar flattening, and a shuffling gait. This disorder was first discovered in the summer of 1991, by D L Viljoen et al., they described three sisters all over the age of 60 with all of the symptoms described above which were similar to those in Rubenstein–Taybi syndrome. The suspected mode of inheritance is of an autosomal recessive manner. Viljoen-Kallis-Voges Syndrome is an extremely rare congenital disorder, and the presentation of symptoms may occur at birth or in infancy. Both males and females may be affected and certain individuals of all racial and ethnic groups. A positive family history may be an important risk factor, since it can be inherited. Currently, the genetic cause of this has not been discovered.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.